Business Context and Reporting Period
Propanc Biopharma, Inc., a Delaware corporation with principal offices in Australia, filed this Form 8-K on May 31, 2024. The filing reports the entry into a material definitive agreement involving the issuance of a convertible promissory note to an investor.
Key Financial Metrics
- Transaction Type: Issuance of a convertible promissory note.
- Principal Amount: $49,200.
- Purchase Price (Net Proceeds): $41,000.
- Interest Charge: One-time charge of 15% ($7,380) applied on the issuance date.
- Total Repayment Obligation: $56,580 (Principal + Interest).
- Maturity Date: March 30, 2025.
- Repayment Schedule: Five installments beginning November 30, 2024 ($28,290) followed by four payments of $7,072.50.
- Conversion Terms: Convertible at the investor's option upon an Event of Default at a price of 65% of the lowest trading price during the 10 trading days prior to conversion (35% discount).
Material Changes
This filing represents a new direct financial obligation and an unregistered sale of equity securities (via the convertible note). The company has incurred a liability of $49,200 in principal plus accrued interest, with proceeds intended for general working capital. No prior comparable period data is provided in this specific filing as it is a current event report rather than a periodic financial statement.
Outlook, Risks, and Contingencies
- Use of Proceeds: General working capital purposes.
- Prepayment: The company retains the right to prepay the note in full at any time without penalty.
- Events of Default: Include failure to pay, failure to issue conversion shares, failure to maintain OTC market listing, failure to comply with SEC reporting, insolvency, or bankruptcy. Upon default, the note becomes immediately due and payable.
- Regulatory Status: The note was issued under the private placement exemption (Section 4(a)(2) and/or Rule 506 of Regulation D).
Investor Verification Checklist
- Verify the company's current cash position to assess ability to meet the first payment of $28,290 due November 30, 2024.
- Confirm the company's continued compliance with SEC reporting requirements and OTC market listing status to avoid triggering an Event of Default.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) and Convertible Promissory Note (Exhibit 4.1) for additional covenants not summarized here.
- Assess the potential dilution impact if the note is converted, given the 35% discount to the lowest trading price.